Multiomic Single-Cell Sequencing Identifies BCR::ABL1 as an Acquired Resistance Mechanism in FLT3+ AML

Vanessa E Kennedy1, Cheryl A C Peretz2, Andrew Koh3

  • 1Department of Medicine, Stanford University, Stanford, California, USA.

Summary

BCR::ABL1 acquisition is a new resistance mechanism in FLT3-mutated acute myeloid leukemia (AML). This study used single-cell sequencing to show BCR::ABL1 emerged alongside FLT3-ITD, driving FLT3 inhibitor resistance in specific AML cells.